Products
...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
Glycekare
Glycekare, A division of Medley Pharmaceutical is thriving since a decade and is by far the largest division of the company.
Division is achieving newer heights through unique formulations & innovative ideas.

Anti Diabetic

Semi Trigem 1
Description
25 million Indians currently have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. As people age, their pancreatic islet cells—the cells that manufacture insulin—fail. The burnout of islet cells is a continuous process of normal aging, but, while those cells fail at the rate of 1% per year in healthy people, they self-destruct at a rate of 5 % per year in people with type 2 diabetes. Studies show that the oral medications may prevent the continuous destruction of pancreatic islets. Early and aggressive treatment with oral medications could preserve islet cells and delay the need for insulin therapy.
Indications
Type II diabetes mellitus uncontrolled by dual drug therapy.
Composition
Each tablet contains:
 

Glimepiride
1 mg

Pioglitazone
7.5 mg

Metformin SR
500 mg

Dosage
As advised by the physician.
Side Effects
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Contraindications
Known hypersensitivity to any of the components.
Presentation
Semi Trigem 1 is available as a strip of 10 tablets.
Semi Trigem 2
Description
25 million Indians currently have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. As people age, their pancreatic islet cells—the cells that manufacture insulin—fail. The burnout of islet cells is a continuous process of normal aging, but, while those cells fail at the rate of 1% per year in healthy people, they self-destruct at a rate of 5 % per year in people with type 2 diabetes. Studies show that the oral medications may prevent the continuous destruction of pancreatic islets. Early and aggressive treatment with oral medications could preserve islet cells and delay the need for insulin therapy.
Indications
Type II diabetes mellitus uncontrolled by dual drug therapy.
Composition
Each tablet contains:
 

Glimepiride
2 mg

Pioglitazone
7.5 mg

Metformin SR
500 mg

Dosage
As advised by the physician.
Side Effects
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Contraindications
Known hypersensitivity to any of the components.
Presentation
Semi Trigem 2 is available as a strip of 10 tablets.
Trigem 1
Description
Type 2 diabetes mellitus is a progressive disorder, and although oral dual therapy is often initially successful, it is associated with a secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia. Later in the course of the disease, the use of combinations of three oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients.

Combination therapy using oral antidiabetic agents with different mechanisms of action can be highly effective in achieving and maintaining target blood glucose levels.
Indications
Type II diabetes mellitus uncontrolled by any dual drug therapy.
Composition
Each tablet contains:
 

Glimepiride
1 mg

Pioglitazone
15 mg

Metformin SR
500 mg

Dosage
One tablet once daily.
Side Effects
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Contraindications
Known hypersensitivity to any of the components.
Presentation
Trigem 1 is available as a strip of 10 tablets.
Trigem 2
Description
Type 2 diabetes mellitus is a progressive disorder, and although oral dual therapy is often initially successful, it is associated with a secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia. Later in the course of the disease, the use of combinations of three oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients.

Combination therapy using oral antidiabetic agents with different mechanisms of action can be highly effective in achieving and maintaining target blood glucose levels.
Indications
Type II diabetes mellitus uncontrolled by any dual drug therapy.
Composition
Each tablet contains:
 

Glimepiride
2 mg

Pioglitazone
15 mg

Metformin SR
500 mg

Dosage
One tablet once daily.
Side Effects
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Contraindications
Known hypersensitivity to any of the components.
Presentation
Trigem 2 is available as a strip of 10 tablets.
Vogli 0.2
Description
It is an alpha-glycosidase inhibitor. It inhibits the conversion of disaccharides into monosaccharide like glucose (Absorbable form), thereby delaying the digestion and absorption of carbohydrates resulting in decreased postprandial hyperglycemia. It is important to control post-challenge hyperglycemia tended to be more strongly related to insulin resistance, higher blood pressure, obesity, and dyslipidemia.
Indications
  • Non-insulin-dependent diabetes mellitus.
  • In insulin dependent diabetes mellitus.
  • Voglibose may also be used in combination with a sulfonylurea when diet plus either voglibose or a sulfonylurea alone do not result in adequate glycemic control.
Composition
Each tablet contains:
 

Voglibose
0.2 mg

Dosage
Dosage must be individualized; not exceeding the maximum recommended dosage of 0.6mg 3 times daily. Voglibose should be taken three times daily at the start (with the first bite) of each main meal.
Side Effects
Gastrointestinal side effects like abdominal pain, diarrhea, and flatulence can occur.
Precautions
Since voglibose is not metabolized and eliminated unchanged by the kidneys, it should not be used in renal failure.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli 0.3
Description
It is an alpha-glycosidase inhibitor. It inhibits the conversion of disaccharides into monosaccharide like glucose (Absorbable form), thereby delaying the digestion and absorption of carbohydrates resulting in decreased postprandial hyperglycemia. It is important to control post-challenge hyperglycemia tended to be more strongly related to insulin resistance, higher blood pressure, obesity, and dyslipidemia.
Indications
  • Non-insulin-dependent diabetes mellitus.
  • In insulin dependent diabetes mellitus.
  • Voglibose may also be used in combination with a sulfonylurea when diet plus either voglibose or a sulfonylurea alone do not result in adequate glycemic control.
Composition
Each tablet contains:
 

Voglibose
0.3 mg

Dosage
Dosage must be individualized; not exceeding the maximum recommended dosage of 0.6mg 3 times daily. Voglibose should be taken three times daily at the start (with the first bite) of each main meal.
Side Effects
Gastrointestinal side effects like abdominal pain, diarrhea, and flatulence can occur.
Precautions
Since voglibose is not metabolized and eliminated unchanged by the kidneys, it should not be used in renal failure.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli GM 1
Description
Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.
Indications
Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients
Composition
Each Tablet consists:
 

Glimepiride
1 mg

Metformin (Sustained Release)
500 mg

Voglibose
0.2 mg

Dosage
One tablet twice daily.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli GM 2
Description
Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.
Indications
Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients
Composition
Each Tablet consists:
 

Glimepiride
2 mg

Metformin (Sustained Release)
500 mg

Voglibose
0.2 mg

Dosage
One tablet twice daily.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli M 0.2
Description
Postprandial hyperglycemia is an independent risk factor for macro vascular complications. However, the normalization of postprandial plasma glucose peaks in clinical practice is recognized as more problematic than the overall management of fasting plasma glucose levels. The causes of PPHG are influenced by many factors which include a rapid flux of glucose from the gut, impaired insulin release, endogenous glucose production by the liver, peripheral insulin resistance. Voglibose in Vogli M reduces postprandial hyperglycemia primarily by interfering with the carbohydrate digesting enzymes and delaying glucose absorption. Metformin in Vogli M reduces Insulin Resistance, decreases glucose absorption & inhibits Gluconeogenesis. Both drug acts on different parameters and gives additive effect in the management of Post Prandial Hyperglycemia and achieves A1C goal.
Indications
  • Post Prandial Hyperglycemia
  • Type 2 diabetes not controlled with diet/ monotherapy
  • Obese Type-2-Diabetic Patients
  • Impaired Glucose Tolerance (IGT)
  • Adjuvant to Insulin therapy in Type-1 Diabetic.
Composition
Each tablet contains:
 

Voglibose
0.2 mg

Metformin
500 mg

Dosage
1 tablet with each major meal
Side Effects
Metallic taste, abdominal distension, Nausea, Vomiting, Diarrhoea.
Contraindication
Pregnancy, Liver disease, Kidney failure.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli M 0.3
Description
Postprandial hyperglycemia is an independent risk factor for macro vascular complications. However, the normalization of postprandial plasma glucose peaks in clinical practice is recognized as more problematic than the overall management of fasting plasma glucose levels. The causes of PPHG are influenced by many factors which include a rapid flux of glucose from the gut, impaired insulin release, endogenous glucose production by the liver, peripheral insulin resistance. Voglibose in Vogli M reduces postprandial hyperglycemia primarily by interfering with the carbohydrate digesting enzymes and delaying glucose absorption. Metformin in Vogli M reduces Insulin Resistance, decreases glucose absorption & inhibits Gluconeogenesis. Both drug acts on different parameters and gives additive effect in the management of Post Prandial Hyperglycemia and achieves A1C goal.
Indications
  • Post Prandial Hyperglycemia
  • Type 2 diabetes not controlled with diet/ monotherapy
  • Obese Type-2-Diabetic Patients
  • Impaired Glucose Tolerance (IGT)
  • Adjuvant to Insulin therapy in Type-1 Diabetic.
Composition
Each tablet contains:
 

Voglibose
0.3 mg

Metformin
500 mg

Dosage
1 tablet with each major meal
Side Effects
Metallic taste, abdominal distension, Nausea, Vomiting, Diarrhoea.
Contraindication
Pregnancy, Liver disease, Kidney failure.
Presentation
Vogli is available as a strip of 10 tablets.
Semi Trigem 1 Forte
Description
25 million Indians currently have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. As people age, their pancreatic islet cells—the cells that manufacture insulin—fail. The burnout of islet cells is a continuous process of normal aging, but, while those cells fail at the rate of 1% per year in healthy people, they self-destruct at a rate of 5 % per year in people with type 2 diabetes. Studies show that the oral medications may prevent the continuous destruction of pancreatic islets. Early and aggressive treatment with oral medications could preserve islet cells and delay the need for insulin therapy.
Indications
Type II diabetes mellitus uncontrolled by dual drug therapy.
Composition
Each tablet contains:
 

Glimepiride
1 mg

Pioglitazone
7.5 mg

Metformin SR
1000 mg

Dosage
As advised by the physician.
Side Effects
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Contraindications
Known hypersensitivity to any of the components.
Presentation
Semi Trigem 1 is available as a strip of 10 tablets.
Semi Trigem 2 Forte
Description
25 million Indians currently have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. As people age, their pancreatic islet cells—the cells that manufacture insulin—fail. The burnout of islet cells is a continuous process of normal aging, but, while those cells fail at the rate of 1% per year in healthy people, they self-destruct at a rate of 5 % per year in people with type 2 diabetes. Studies show that the oral medications may prevent the continuous destruction of pancreatic islets. Early and aggressive treatment with oral medications could preserve islet cells and delay the need for insulin therapy.
Indications
Type II diabetes mellitus uncontrolled by dual drug therapy.
Composition
Each tablet contains:
 

Glimepiride
2 mg

Pioglitazone
7.5 mg

Metformin SR
1000 mg

Dosage
As advised by the physician.
Side Effects
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Contraindications
Known hypersensitivity to any of the components.
Presentation
Semi Trigem 2 is available as a strip of 10 tablets.
Vogli GM 1 Forte
Description
Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.
Indications
Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients
Composition
Each Tablet consists:
 

Glimepiride
1 mg

Metformin (Sustained Release)
500 mg

Voglibose
0.3 mg

Dosage
One tablet twice daily.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli GM 2 Forte
Description
Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.
Indications
Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients
Composition
Each Tablet consists:
 

Glimepiride
2 mg

Metformin (Sustained Release)
500 mg

Voglibose
0.3 mg

Dosage
One tablet twice daily.
Presentation
Vogli is available as a strip of 10 tablets.
Glytrin
Indications
• Type II Diabetes
Composition
Each Tablet consists:
 

Teneligliptin
20 mg

Presentation
Glytrin is available as a strip of 10 tablets.
Glytrin Met
Indications
• Type II Diabetes
Composition
Each Tablet consists:
 

Teneligliptin
20 mg

Metformin (ER)
500 mg

Presentation
Glytrin Met is available as a strip of 10 tablets.